Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Daclizumab (Zinbryta) and dimethyl fumarate (Tecfidera) are both medications used to treat relapsing forms of multiple sclerosis (MS) in adults. However, they belong to different medication classes and have distinct characteristics. Daclizumab is a monoclonal antibody that was available as an injection but has been discontinued due to safety concerns, including liver injury and immune-related problems. In contrast, dimethyl fumarate is a fumaric acid derivative available as an oral capsule, which you take twice a day. Dimethyl fumarate comes has both a brand and a generic version. Common side effects of dimethyl fumarate include stomach upset and flushing. Dimethyl fumarate can also weaken your immune system, increasing the risk of infections, and requires regular blood tests to monitor liver health and white blood cell counts.
Zinbryta (daclizumab)
Dimethyl fumarate (Tecfidera)
Zinbryta (daclizumab)
Dimethyl fumarate (Tecfidera)
Summary of Zinbryta vs. Tecfidera
Summary for Monoclonal antibody
Zinbryta (daclizumab) is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. It's no longer available in the United States, because it was discontinued.
Summary for Fumaric acid derivative
Prescription only
Dimethyl fumarate (Tecfidera) is used to treat adults with certain types of multiple sclerosis (MS), a condition that affects your nervous system. This medication is a disease-modifying therapy (DMT) that belongs to the drug class called fumaric acid derivatives. Dimethyl fumarate (Tecfidera) is available as a brand-name medication and a lower-cost generic. The capsules are taken by mouth twice per day. The most common side effects are stomach upset and flushing (e.g., facial warmth, redness, burning sensation).